|
Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER). |
|
|
Honoraria - Clinical Care Options; Dava Oncology |
Consulting or Advisory Role - Lumicell; Novartis; Puma Biotechnology |
Research Funding - Merck (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - Merck; Tesaro |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Hengrui Therapeutics; Immunomedics; Mylan; Myriad Genetics; OncoPep; OncoPep; Puma Biotechnology |
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Merck (Inst); OncoPep (Inst); PharmaMar (Inst) |
|
|
Consulting or Advisory Role - Dark Canyon Labs (I); MOTUS (I); Remedy Partners (I) |
Research Funding - Puma Biotechnology (Inst) |
|
|
Consulting or Advisory Role - Foundation Medicine; InfiniteMD; Lilly; Puma Biotechnology |
Research Funding - Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Advance Medical; Applied Genetic Technologies Corporation (I); Beam Therapeutics (I); Biogen (I); Blue Cross Blue Shield Association (I); Crico; Editas Medicine (I); GenSight Biologics (I); Harvard Medical School; infiniteMD (I); RBC Investments (Inst); Sanofi (I); Vedere Bio (I); WAVE Life Sciences (I) |
|
|
Consulting or Advisory Role - Outcomes4Me |
Expert Testimony - Morrison Mahoney |
Other Relationship - Academy of Managed Care Pharmacy |
|
|
Consulting or Advisory Role - bioTheranostics; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals |
Research Funding - bioTheranostics |